CA2902841A1 - Methods and compositions for detecting pancreatic cancer - Google Patents

Methods and compositions for detecting pancreatic cancer Download PDF

Info

Publication number
CA2902841A1
CA2902841A1 CA2902841A CA2902841A CA2902841A1 CA 2902841 A1 CA2902841 A1 CA 2902841A1 CA 2902841 A CA2902841 A CA 2902841A CA 2902841 A CA2902841 A CA 2902841A CA 2902841 A1 CA2902841 A1 CA 2902841A1
Authority
CA
Canada
Prior art keywords
pancreatic cancer
protein
level
cancer biomarker
homo sapiens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2902841A
Other languages
English (en)
French (fr)
Inventor
Lewis K. Pannell
Jana ROCKER
Jack DI PALMA
Carlo Contreras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creatics LLC
Original Assignee
Creatics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creatics LLC filed Critical Creatics LLC
Publication of CA2902841A1 publication Critical patent/CA2902841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2902841A 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer Abandoned CA2902841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780574P 2013-03-13 2013-03-13
US61/780,574 2013-03-13
PCT/US2014/026857 WO2014160499A2 (en) 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer

Publications (1)

Publication Number Publication Date
CA2902841A1 true CA2902841A1 (en) 2014-10-02

Family

ID=50933479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902841A Abandoned CA2902841A1 (en) 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer

Country Status (7)

Country Link
US (3) US20160033511A1 (enExample)
EP (1) EP2972375A2 (enExample)
JP (3) JP6646571B2 (enExample)
AU (3) AU2014243704A1 (enExample)
CA (1) CA2902841A1 (enExample)
HK (1) HK1214652A1 (enExample)
WO (1) WO2014160499A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096785A1 (en) * 2014-12-19 2016-06-23 F. Hoffmann-La Roche Ag Identification of transglutaminase substrates and uses therefor
US10006915B2 (en) 2014-12-19 2018-06-26 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11054425B2 (en) 2014-12-19 2021-07-06 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
DK2140269T3 (da) 2007-03-27 2013-12-16 Immunovia Ab Proteinsignatur/markører til at detektere adenocarcinom
EP3620185A1 (en) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CA2848162C (en) 2011-09-12 2023-03-14 Creatics Llc Non-invasive methods of detecting target molecules
WO2013152860A2 (en) * 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
ME03326B (me) 2013-03-15 2019-10-20 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
DK3387898T3 (da) 2013-03-15 2020-08-03 Mayo Found Medical Education & Res Identificering og monitorering af monoklonale immunglobuliner ved hjælp af molekylvægt
EP3159695A3 (en) * 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Methods for diagnosing pancreatic cancer
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
CN106461678A (zh) * 2014-05-26 2017-02-22 奥林巴斯株式会社 胰腺癌判定方法
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
EP3230314B1 (en) 2014-12-08 2023-05-03 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
US20160271120A1 (en) * 2015-03-17 2016-09-22 Oakdene Holdings Llc Pharmaceutical composition for cleansing of the gastrointestinal tract
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
US20180306788A1 (en) * 2015-04-07 2018-10-25 President And Fellows Of Harvard College Compositions and methods for modulating hydroxylation of acc2 by phd3
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
JP2018513141A (ja) * 2015-04-20 2018-05-24 コンセジョ スペリオール デ インベスティガショネス シエンティフィカス ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
US10823735B2 (en) * 2015-09-03 2020-11-03 The University Of Hong Kong Monoclonal antibody for predicting tamoxifen response in breast cancer patients
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
CN105296613A (zh) * 2015-09-24 2016-02-03 郑州市职业病防治院 一种人TERF1基因rs3863242位点多态性检测技术
US11371099B2 (en) 2015-11-30 2022-06-28 Mayo Foundation For Medical Education And Research HEATR1 as a marker for chemoresistance
CN105785013A (zh) * 2016-04-21 2016-07-20 卢连伟 一种辅助检测胰腺癌的胶体金免疫层析试纸及其制备方法
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
EP3484448B1 (en) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
EP3523647B1 (en) 2016-09-07 2024-06-26 Mayo Foundation for Medical Education and Research Identification and monitoring of cleaved immunoglobulins by molecular mass
CN107655985B (zh) * 2017-08-25 2020-05-26 南京农业大学 一种基于lc-ms-ms技术的体内蛋白质营养的评价方法
EP3681528B1 (en) 2017-09-13 2025-07-23 Mayo Foundation for Medical Education and Research Identification and monitoring of apoptosis inhibitor of macrophage
EP3681907A4 (en) 2017-09-13 2021-07-07 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN J-CHAINS
JP2021520493A (ja) * 2018-04-03 2021-08-19 クリエイティクス エルエルシー 胃腸洗浄液試料における免疫グロブリンのグリカン結合パターンを評価するがん検出方法
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020101878A2 (en) * 2018-10-29 2020-05-22 The Johns Hopkins University Rasopathy treatment
WO2020223646A1 (en) * 2019-05-02 2020-11-05 Creatics Llc Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples
BR112021026192A2 (pt) * 2019-06-24 2022-06-07 Urteste S A Marcador de diagnóstico para câncer pancreático
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE
WO2021076036A1 (en) * 2019-10-18 2021-04-22 Reccan Diagnostics Ab Apparatuses and methods for detection of pancreatic cancer
JP7693718B2 (ja) * 2020-05-26 2025-06-17 エフ． ホフマン－ラ ロシュ アーゲー 定量器－確認器比チェックのために顧客質量分析機器を較正するためのコンピュータ実装方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
US20230272359A1 (en) * 2020-07-20 2023-08-31 Dana-Farber Cancer Institute, Inc. Methods and compositions for treatment and prevention of coronavirus infection
KR102448586B1 (ko) * 2020-10-08 2022-09-27 가톨릭대학교 산학협력단 췌장암 환자의 항암제 치료 반응성 예측용 마커
JP7825633B2 (ja) * 2020-12-08 2026-03-06 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
CN112461915B (zh) * 2020-12-08 2024-07-12 杭州汇健科技有限公司 一种与药物敏感相关的特征分子筛选、药敏程度检测、细胞亚型检测的方法
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
US20240229154A9 (en) * 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
WO2022221168A1 (en) * 2021-04-11 2022-10-20 Khurana Vikas System for pulse cycle harmonized ventilation and the method thereof
CN117813120A (zh) * 2021-06-07 2024-04-02 旗舰先锋创新Vii有限责任公司 用于靶向递送治疗剂的组合物和方法
EP4405681A4 (en) * 2021-09-20 2025-08-06 Droplet Biosciences Inc DIAGNOSTIC DRAINAGE FLUID
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics
US12416626B2 (en) * 2022-07-22 2025-09-16 Droplet Biosciences, Inc. Methods for evaluating candidate therapy efficacy based on changes in lymphatic fluid biomarkers
WO2024086298A2 (en) * 2022-10-20 2024-04-25 The Johns Hopkins University Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof
WO2024206856A2 (en) * 2023-03-30 2024-10-03 Thomas Jefferson University Dna-dependent synthesis of rna by dna polymerase theta variants

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28937T1 (de) * 1982-08-09 1987-08-15 Centocor Inc Immunotest fuer kohlehydrat-antigen-determinant.
JPH0673470B2 (ja) * 1986-07-15 1994-09-21 協和醗酵工業株式会社 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US6924153B1 (en) 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
JPH11225800A (ja) * 1998-02-10 1999-08-24 Kureha Chem Ind Co Ltd 体液を用いた癌検出方法及びキット
US6447763B1 (en) * 1998-06-12 2002-09-10 Ian L. Gordon Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells
EP1298205A4 (en) * 2000-07-03 2004-06-16 Mochida Pharm Co Ltd NEW LIPASE
WO2003014298A2 (en) * 2001-08-03 2003-02-20 Origene Technologies, Inc. Full-length prostate selective polynucleotides and polypeptides
US7291324B2 (en) * 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
US20040219572A1 (en) * 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
WO2005053512A2 (en) * 2003-11-26 2005-06-16 Dana-Farber Cancer Institute, Inc. Animal models of pancreatic adenocarcinoma and uses therefor
ATE427499T1 (de) 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
CA2645125A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
EP2816122A1 (en) * 2008-02-15 2014-12-24 Mayo Foundation For Medical Education And Research Detecting neoplasm from a stool sample
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
JP5312684B2 (ja) * 2009-05-04 2013-10-09 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｄｐｐｉｖ／セプラーゼの使用
WO2011027311A2 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
CN102762984A (zh) * 2009-11-05 2012-10-31 弗吉尼亚大学专利基金会 用于检测作为癌症生物标志的网蛋白-1的组合物和方法
AU2011260390B2 (en) * 2010-06-01 2016-11-24 Ernst-Moritz-Arndt Universitat Greifswald Means and methods for diagnosing pancreatic cancer in a subject
EP2603622A4 (en) * 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
AU2011351990A1 (en) * 2010-12-29 2013-07-18 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
JP5984795B2 (ja) * 2011-04-05 2016-09-06 オリンパス株式会社 膵疾患を検出するためのデータを収集する方法
CA2848162C (en) * 2011-09-12 2023-03-14 Creatics Llc Non-invasive methods of detecting target molecules

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096785A1 (en) * 2014-12-19 2016-06-23 F. Hoffmann-La Roche Ag Identification of transglutaminase substrates and uses therefor
US10006915B2 (en) 2014-12-19 2018-06-26 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US10788495B2 (en) 2014-12-19 2020-09-29 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11054425B2 (en) 2014-12-19 2021-07-06 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11268120B2 (en) 2014-12-19 2022-03-08 Roche Sequencing Solutions, Inc. Identification of transglutaminase substrates and uses therefor

Also Published As

Publication number Publication date
JP2022141755A (ja) 2022-09-29
JP7109008B2 (ja) 2022-08-10
AU2020202066B2 (en) 2022-06-02
EP2972375A2 (en) 2016-01-20
WO2014160499A2 (en) 2014-10-02
AU2020202066A1 (en) 2020-04-09
US20160033511A1 (en) 2016-02-04
AU2022224782A1 (en) 2022-09-22
JP2016519285A (ja) 2016-06-30
US20220128563A1 (en) 2022-04-28
JP2020091295A (ja) 2020-06-11
JP6646571B2 (ja) 2020-02-14
AU2014243704A1 (en) 2015-09-10
WO2014160499A3 (en) 2015-01-29
US20190234951A1 (en) 2019-08-01
HK1214652A1 (zh) 2016-07-29

Similar Documents

Publication Publication Date Title
AU2020202066B2 (en) Methods and compositions for detecting pancreatic cancer
US20070292869A1 (en) Compositions and Methods for Analyzing Renal Cancer
US20230063827A1 (en) Methods and Compositions for the Diagnosis of Ovarian Cancer
KR20090034961A (ko) 폐암 진단 검사
US20100216654A1 (en) Biomarkers of prostate cancer and uses thereof
EP2452948B1 (en) New tumor marker
Zhang et al. Contribution of biomarkers for pancreatic cancer-associated new-onset diabetes to pancreatic cancer screening
KR101388711B1 (ko) 암 진단 마커로서의 보체 ｃ９
EP3144676B1 (en) Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer
US20230145939A1 (en) Marker composition for cancer diagnosis or prognosis based on exosome overexressing gcc2
US20220196670A1 (en) Endometrial receptivity determination
KR100883530B1 (ko) 대장암 진단용 단백질 마커 아데노실호모시스테이나제 및이에 대한 항체를 포함하는 대장암 진단키트
CN108047327B (zh) 一种检测骨关节炎的生物标志物及其应用
JP4795353B2 (ja) 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素１（ｃｐｓ１）の使用
US20150004621A1 (en) Biological marker for early cancer detection and methods for cancer detection (bf819)
WO2020223646A1 (en) Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples
KR20180117918A (ko) Mfap5 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
Du et al. Abnormal N-glycosylated CPXM1 promotes gastric cancer metastasis through ITGB2/FAK pathway
AU2014203702B2 (en) New tumor marker
KR20080092490A (ko) 대장암 진단용 단백질 마커 켈그라눌린 ａ와 켈그라눌린 ｂ및 이들 각각에 대한 항체를 포함하는 대장암 진단키트
HK1166329B (en) New tumor marker
HK1166329A (en) New tumor marker

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

FZDE Discontinued

Effective date: 20220426

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDE Discontinued

Effective date: 20240228